Malignant melanoma patient outcomes have changed drastically with the emergence of immune checkpoint inhibitors (ICI) and BRAF-targeted therapies and the lethality of advanced disease has decreased significantly in the past 10 years [1,2]. Here, BRAF is linked to melanoma.